Literature DB >> 28474276

Sphingosine Toxicity in EAE and MS: Evidence for Ceramide Generation via Serine-Palmitoyltransferase Activation.

Lawrence G Miller1, Jennifer A Young1, Swapan K Ray2, Guanghu Wang3, Sharad Purohit4, Naren L Banik1, Somsankar Dasgupta5.   

Abstract

Multiple sclerosis (MS) is a demyelinating disorder characterized by massive neurodegeneration and profound axonal loss. Since myelin is enriched with sphingolipids and some of them display toxicity, biological function of sphingolipids in demyelination has been investigated in MS brain tissues. An elevation of sphingosine with a decrease in monoglycosylceramide and psychosine (myelin markers) was observed in MS white matter and plaque compared to normal brain tissue. This indicated that sphingosine toxicity might mediate oligodendrocyte degeneration. To explain the source of sphingosine accumulation, total sphingolipid profile was investigated in Lewis rats after inducing experimental autoimmune encephalomyelitis (EAE) and also in human oligodendrocytes in culture. An intermittent increase in ceramide followed by sphingosine accumulation in EAE spinal cord along with a stimulation of serine-palmitoyltransferase (SPT) activity was observed. Apoptosis was identified in the lumbar spinal cord, the most prominent demyelinating area, in the EAE rats. TNFα and IFNγ stimulation of oligodendrocytes in culture also led to an accumulation of ceramide with an elevation of sphingosine. Ceramide elevation was drastically blocked by myriocin, an inhibitor of SPT, and also by FTY720. Myriocin treatment also protected oligodendrocytes from cytokine mediated apoptosis or programmed cell death. Hence, we propose that sphingosine toxicity may contribute to demyelination in both EAE and MS, and the intermittent ceramide accumulation in EAE may, at least partly, be mediated via SPT activation, which is a novel observation that has not been previously reported.

Entities:  

Keywords:  Ceramide; Demyelination; EAE; Multiple sclerosis; Normal appearing white matter; Serine-palmitoyltransferase

Mesh:

Substances:

Year:  2017        PMID: 28474276     DOI: 10.1007/s11064-017-2280-2

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  65 in total

Review 1.  De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway.

Authors:  Alfred H Merrill
Journal:  J Biol Chem       Date:  2002-05-13       Impact factor: 5.157

2.  Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis.

Authors:  Jingdong Qin; Evgeny Berdyshev; Jonathan Goya; Viswanathan Natarajan; Glyn Dawson
Journal:  J Biol Chem       Date:  2010-03-09       Impact factor: 5.157

Review 3.  Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy.

Authors:  Wenjing Zheng; Jessica Kollmeyer; Holly Symolon; Amin Momin; Elizabeth Munter; Elaine Wang; Samuel Kelly; Jeremy C Allegood; Ying Liu; Qiong Peng; Harsha Ramaraju; M Cameron Sullards; Myles Cabot; Alfred H Merrill
Journal:  Biochim Biophys Acta       Date:  2006-08-22

4.  Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.

Authors:  K A Krown; M T Page; C Nguyen; D Zechner; V Gutierrez; K L Comstock; C C Glembotski; P J Quintana; R A Sabbadini
Journal:  J Clin Invest       Date:  1996-12-15       Impact factor: 14.808

5.  Ceramide synthase 6 plays a critical role in the development of experimental autoimmune encephalomyelitis.

Authors:  Susanne Schiffmann; Nerea Ferreiros; Kerstin Birod; Max Eberle; Yannick Schreiber; Waltraud Pfeilschifter; Ulf Ziemann; Sandra Pierre; Klaus Scholich; Sabine Grösch; Gerd Geisslinger
Journal:  J Immunol       Date:  2012-04-27       Impact factor: 5.422

Review 6.  Sphingolipids in multiple sclerosis.

Authors:  Arundhati Jana; Kalipada Pahan
Journal:  Neuromolecular Med       Date:  2010-07-07       Impact factor: 3.843

7.  The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2.

Authors:  Steven W Paugh; Shawn G Payne; Suzanne E Barbour; Sheldon Milstien; Sarah Spiegel
Journal:  FEBS Lett       Date:  2003-11-06       Impact factor: 4.124

8.  Sphingosine induces apoptosis in MKN-28 human gastric cancer cells in an SDK-dependent manner.

Authors:  Takeshi Kanno; Takaaki Nishimoto; Yumiko Fujita; Akinobu Gotoh; Takashi Nakano; Tomoyuki Nishizaki
Journal:  Cell Physiol Biochem       Date:  2012-09-20

9.  Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in the spinal cord of rats during acute experimental allergic encephalomyelitis.

Authors:  M Matsuda; N Tsukada; C S Koh; T Iwahashi; K Shimada; N Yanagisawa
Journal:  Autoimmunity       Date:  1994       Impact factor: 2.815

Review 10.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08
View more
  13 in total

1.  Insights into abnormal sphingolipid metabolism in multiple sclerosis: targeting ceramide biosynthesis as a unique therapeutic strategy.

Authors:  Somsankar Dasgupta; Swapan K Ray
Journal:  Ther Targets Neurol Dis       Date:  2017-10-02

2.  Metabolomic Signature in Sera of Multiple Sclerosis Patients during Pregnancy.

Authors:  Claudia Rossi; Ilaria Cicalini; Mirco Zucchelli; Maria di Ioia; Marco Onofrj; Luca Federici; Piero Del Boccio; Damiana Pieragostino
Journal:  Int J Mol Sci       Date:  2018-11-14       Impact factor: 5.923

Review 3.  Ceramide and Sphingosine Regulation of Myelinogenesis: Targeting Serine Palmitoyltransferase Using microRNA in Multiple Sclerosis.

Authors:  Somsankar Dasgupta; Swapan K Ray
Journal:  Int J Mol Sci       Date:  2019-10-11       Impact factor: 5.923

4.  In Human and Mouse Spino-Cerebellar Tissue, Ataxin-2 Expansion Affects Ceramide-Sphingomyelin Metabolism.

Authors:  Nesli-Ece Sen; Aleksandar Arsovic; David Meierhofer; Susanne Brodesser; Carola Oberschmidt; Júlia Canet-Pons; Zeynep-Ece Kaya; Melanie-Vanessa Halbach; Suzana Gispert; Konrad Sandhoff; Georg Auburger
Journal:  Int J Mol Sci       Date:  2019-11-21       Impact factor: 5.923

Review 5.  Sphingolipids as prognostic biomarkers of neurodegeneration, neuroinflammation, and psychiatric diseases and their emerging role in lipidomic investigation methods.

Authors:  Daan van Kruining; Qian Luo; Gerhild van Echten-Deckert; Michelle M Mielke; Andrew Bowman; Shane Ellis; Tiago Gil Oliveira; Pilar Martinez-Martinez
Journal:  Adv Drug Deliv Rev       Date:  2020-04-28       Impact factor: 15.470

Review 6.  Molecular Effects of FDA-Approved Multiple Sclerosis Drugs on Glial Cells and Neurons of the Central Nervous System.

Authors:  Kim M A De Kleijn; Gerard J M Martens
Journal:  Int J Mol Sci       Date:  2020-06-13       Impact factor: 5.923

Review 7.  Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development.

Authors:  Victor García-González; José Fernando Díaz-Villanueva; Octavio Galindo-Hernández; Israel Martínez-Navarro; Gustavo Hurtado-Ureta; Abril Alicia Pérez-Arias
Journal:  Int J Mol Sci       Date:  2018-08-26       Impact factor: 5.923

8.  Diverse Biological Functions of Sphingolipids in the CNS: Ceramide and Sphingosine Regulate Myelination in Developing Brain but Stimulate Demyelination during Pathogenesis of Multiple Sclerosis.

Authors:  Somsankar Dasgupta; Swapan K Ray
Journal:  J Neurol Psychol       Date:  2017-12-23

Review 9.  Regulation of Oligodendrocyte Functions: Targeting Lipid Metabolism and Extracellular Matrix for Myelin Repair.

Authors:  Davide Marangon; Marta Boccazzi; Davide Lecca; Marta Fumagalli
Journal:  J Clin Med       Date:  2020-02-08       Impact factor: 4.241

10.  Distinctive sphingolipid patterns in chronic multiple sclerosis lesions.

Authors:  Maria Podbielska; Zdzislaw M Szulc; Toshio Ariga; Anna Pokryszko-Dragan; Wojciech Fortuna; Małgorzata Bilinska; Ryszard Podemski; Ewa Jaskiewicz; Ewa Kurowska; Robert K Yu; Edward L Hogan
Journal:  J Lipid Res       Date:  2020-08-07       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.